Endo Pharmaceuticals Subsidiary Receives FDA Approval for Toresmide

Qualitest Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Toresmide tablets (generic Demadex®) in 5 mg, 10 mg, 20 mg and 100 mg strengths. Toresmide tablets are indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease, and for the treatment of hypertension alone or in combination with other antihypertensive agents. Qualitest is a wholly owned subsidiary of Endo Pharmaceuticals ENDP